Christopher J. Coughlin Sells 878 Shares of Centene Co. (NYSE:CNC) Stock

Centene Co. (NYSE:CNCGet Free Report) Director Christopher J. Coughlin sold 878 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $76.75, for a total value of $67,386.50. Following the sale, the director now directly owns 25,504 shares of the company’s stock, valued at $1,957,432. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Centene Trading Down 3.5 %

NYSE:CNC opened at $74.63 on Friday. Centene Co. has a 52-week low of $60.83 and a 52-week high of $81.42. The company has a market capitalization of $39.83 billion, a PE ratio of 14.84, a price-to-earnings-growth ratio of 1.00 and a beta of 0.41. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.66. The stock has a fifty day simple moving average of $75.47 and a 200-day simple moving average of $75.63.

Centene (NYSE:CNCGet Free Report) last issued its quarterly earnings data on Friday, April 26th. The company reported $2.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.17. The firm had revenue of $40.41 billion during the quarter, compared to the consensus estimate of $36.43 billion. Centene had a return on equity of 14.19% and a net margin of 1.76%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.11 EPS. On average, equities research analysts expect that Centene Co. will post 6.82 earnings per share for the current fiscal year.

Institutional Trading of Centene

Large investors have recently made changes to their positions in the stock. Operose Advisors LLC purchased a new position in shares of Centene during the third quarter valued at approximately $25,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Centene during the 4th quarter worth $25,000. Rise Advisors LLC acquired a new stake in shares of Centene during the first quarter worth $25,000. Riggs Asset Managment Co. Inc. purchased a new stake in shares of Centene in the fourth quarter valued at $32,000. Finally, Headinvest LLC acquired a new position in Centene in the third quarter valued at $35,000. Institutional investors and hedge funds own 93.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CNC shares. upgraded shares of Centene from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 29th. Oppenheimer reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Centene in a report on Monday, April 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $90.00 target price on shares of Centene in a research note on Thursday, April 4th. Stephens restated an “equal weight” rating and issued a $85.00 price target (down from $92.00) on shares of Centene in a research note on Thursday, March 21st. Finally, Barclays increased their price objective on Centene from $101.00 to $104.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from, the company presently has an average rating of “Moderate Buy” and an average target price of $85.23.

Get Our Latest Research Report on CNC

About Centene

(Get Free Report)

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.

Recommended Stories

Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with's FREE daily email newsletter.